Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337907 · ClinicalTrials.gov registry record · Phase 2
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT02337907: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT02337907 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 329 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02337907, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
Primary Outcome
Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB consists of 9 validated components. Raw scores on each of the 9 NTB tests were converted to z-scores using the baseline means and standard deviations (SDs) for each test. The resultant z-scores were averaged to obtain a total z-score, incorporating all 9 NTB tests. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is eq
Interventions
- DRUG Placebo
- DRUG Donepezil
- DRUG BI 409306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2017-10-10 |
| Phase | Phase 2 |
What the finished NCT02337907 record still lists
NCT02337907 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02337907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02337907 about?
NCT02337907 is a clinical study titled "BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.". The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
What is the current status of trial NCT02337907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2015-01-21. Estimated completion is 2017-10-10.
What interventions are being tested in trial NCT02337907?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG), BI 409306 (DRUG).
Who is sponsoring clinical trial NCT02337907?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02337907's enrollment target sits among peer trials
329 146th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI